• Iaterion is a bio-pharmaceutical company developing novel nuclear receptor modulators.

  • Iaterion's platform is based on the Company's discovery of nuclear receptor reprograming agents.

  • Nuclear receptors are targets for multiple diseases, including cancer, diabetes, cardiovascular, autoimmune and metabolic disorders.

  • Brevenal

    Brevenal (C39H60O8; MW 656.4043) is manufactured from a proprietary strain of K. brevis in a biotechnology facility, under photosynthetic conditions. The compound is isolated from the cultured organism.
  • Iaterion is a bio-pharmaceutical company developing novel nuclear receptor modulators.

  • Iaterion's platform is based on the Company's discovery of nuclear receptor reprograming agents.

  • Nuclear receptors are targets for multiple diseases, including cancer, diabetes, cardiovascular, autoimmune and metabolic disorders.

  • Brevenal

    Brevenal (C39H60O8; MW 656.4043) is manufactured from a proprietary strain of K. brevis in a biotechnology facility, under photosynthetic conditions. The compound is isolated from the cultured organism.